Business Wire

RQM+™ Launches Fern.ai™

Share

RQM+, the world’s leading MedTech service provider, today announced the launch of Fern.ai, the first human-in-the-loop artificial intelligence (AI) platform that standardizes all aspects of clinical evidence literature review for regulatory affairs professionals – delivering audit-ready, exportable results in 60 percent less time than a manual process and 40 percent less time than alternative technology platforms. Fern.ai is the first offering from RQM+ Technology Solutions, an independent business unit dedicated to helping the life sciences community improve patient outcomes by bringing life-improving products to market more quickly and efficiently through advanced technology platforms.

“Fern.ai empowers clinical, quality and regulatory affairs professionals to focus on quality by automating laborious and frustrating tasks through its human-in-the-loop AI technology,” said RQM+ CEO Margaret Keegan. “With the largest global team of MedTech regulatory and quality consultants, RQM+ is in the best position of any organization to identify time-consuming bottlenecks in the regulatory process and design technologies to eliminate those frustrations for the regulatory community. Through our Technology Solutions business unit, we are proud to introduce platforms like Fern.ai that give regulatory professionals the freedom to focus on strategic, scientific tasks and the confidence to know that the clinical evidence they submit meets the highest quality standards.”

Fern.ai is the only comprehensive platform that covers the entire clinical evidence evaluation process, including literature review strategy, queries, screening, appraisal and data extraction from full-text articles. Through digitization, automation and integration, Fern.ai helps MedTech companies, regulators and service providers generate audit-ready documents in 60 percent less time than a traditional, manual process and 40 percent less time than alternative technology platforms.

“We refer to Fern.ai as human-in-the-loop AI technology because the platform empowers the user by providing recommendations,” said Chief Digital and Technology Officer Alaric Jackson. “Fern.ai streamlines your process, ensures consistency and reduces errors by handling laborious and repetitive tasks, such as screening references and data extraction, but keeps you in the driver’s seat by letting the user make the final call on all recommendations. The judgment and expertise of a highly skilled regulatory professional is irreplaceable and critical to achieve a successful outcome. In addition, Fern.ai learns from these interactions – making the whole end-to-end process increasingly efficient and delivering a high-quality outcome.”

Fern.ai was originally developed in 2020 by Giotto.ai and marketed as Giotto Compliance. RQM+ acquired Giotto Compliance in February 2023.

For more information, visit Fern.ai or the Fern.ai booth at MedTech Summit in Brussels from June 19-23.

About RQM+
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. Building upon 40 years of regulatory expertise, we also provide comprehensive clinical trial, lab, and reimbursement services, and technology solutions – reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics. With more former FDA, Medicines in Healthcare products Regulatory Agency (MHRA) and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media: Rob Pepper, +1.301.254.6100, rpepper@rqmplus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Integrates with Assembla to Streamline Bug Tracking for Development Teams3.6.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced its partnership with Assembla, a robust cloud-based platform for version control and project management. This collaboration enables software development teams to streamline their bug tracking processes and improve overall productivity. LambdaTest offers developers an exhaustive list of cloud-based testing solutions, including cross-browser compatibility testing, Web and App automation testing, and Real Device testing. Assembla users can now easily integrate with the LambdaTest platform to seamlessly mark bugs with detailed screenshots and assign them to team members. "This integration between LambdaTest and Assembla allows development teams to optimize their testing and bug tracking processes," said Mayank Bhola, Co-Founder and Head of Product at LambdaTest. "By connecting these platforms, teams can maintain uninterrupted workflow while ensuring thorough documentation and tracking of issues discovered during

The Future of AI in the AEC Industry Unveiled at BST Global’s 2025 AI Summit3.6.2025 17:41:00 EEST | Press release

BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, hosted its second annual AI Summit, May 6–8, 2025, in Palm Beach, FL. The premier event brought together 12 thought leaders from some of the world’s most influential firms, including Arcadis, Arup, AtkinsRéalis, Gensler, GHD, Jacobs, Mott MacDonald, NVIDIA, Parsons, Stantec, and WSP to share insights on how AI is reshaping the future of the AEC industry. Attendees as well as the broader AEC community praised the 2025 AI Summit for its timely content and line-up of industry trailblazers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603538561/en/ BST Global Chief Executive Officer Javier A. Baldor officially kicks off the AI Summit’s first full day of sessions by presenting his perspective on the driving forces impacting the AEC industry and the world at large. He shares three key ways AI and big data will transform nearly

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 20253.6.2025 17:30:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia (ET), and support its potential to be a disease modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET)." Key Incyte abstracts accepted for presentation at EHA include: Late-Breaking Or

European Commission Approves ADCETRIS ® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD3.6.2025 17:12:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity (TRMB) and non-inferior progression-free survival (PFS) in comparison to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of ca

Automotive Industry Shifts Gears As Talent and Technology Take Center Stage3.6.2025 17:00:00 EEST | Press release

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 130 leaders across automotive and tire manufacturers, original equipment manufacturers, engineering procurement companies and systems integrators across 15 countries, revealing a sector rapidly embracing change to stay competitive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603797393/en/ Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges. Workforce pressures have emerged as the most urgent challenge for automotive companies, signaling a significant shift from last year’s findings. At the same time, concerns around cybersecurity have declined, suggesti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye